AstraZeneca PLC

AZN

Healthcare|Drug Manufacturers - General|UK

$202.83

-0.66 (-0.32%)

DCF (FCF)

$71.68

Earnings Power

$36.18

Upcoming Data Readouts (40)

Aug 2026

Est. completion

P3ER-Positive HER2-Negative Breast Cancer

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252n=1,370

Aug 2026

Est. completion

P3Gastric Cancer, Adenocarcinoma

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934n=490

Sep 2026

Est. completion

Atypical Hemolytic Uremic Syndrome

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

NCT07218536n=200

Sep 2026

Est. completion

P3Metastatic Non-small Cell Lung Cancer

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814n=744

Oct 2026

Est. completion

P3AMI

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

NCT05764057n=450

Oct 2026

Est. completion

Chronic Lymphocytic Leukaemia (CLL)

Retention Rate of Acalabrutinib in a Non-interventional Setting

NCT05645172n=137

Oct 2026

Est. completion

P4Asthma

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300n=75

Nov 2026

Est. completion

P1P2Esophageal Adenocarcinoma

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

NCT02962063n=64

Nov 2026

Est. completion

P3Cutaneous Lupus Erythematosus

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737n=302

Dec 2026

Est. completion

P3Oropharyngeal Cancer

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

NCT04116047n=785

Dec 2026

Est. completion

P3Metastatic Castration-resistant Prostate Cancer (mCRPC)

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

NCT03903835n=750

Dec 2026

Est. completion

COPD

Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry

NCT06974981n=420

Dec 2026

Est. completion

Heart Failure With Preserved Ejection Fraction (HFPEF)

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

NCT07185100n=600

Dec 2026

Est. completion

Pan-tumor(NSCLC, GYN Cancers, BTC and UC)

A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

NCT07404202n=2,100

Feb 2027

Est. completion

P1Refractory Systemic Lupus Erythematosus

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

NCT06530849n=18

Feb 2027

Est. completion

P2NSCLC

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NCT04716946n=13

Feb 2027

Est. completion

P3Diffuse Large B-Cell Lymphoma

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772n=611

Mar 2027

Est. completion

Lupus Erythematosus, Systemic

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

NCT05141201n=1,620

Mar 2027

Est. completion

P4Asthma

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689n=1,511

May 2027

Est. completion

P2Metastatic Colorectal Cancer

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695n=120

Awaiting Results (21)

Trials past primary completion date but still active — data readout may be imminent.

Apr 2026

A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

NCT06897748

Apr 2026

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

NCT04136171

Mar 2026

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123

Mar 2026

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577

Mar 2026

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

NCT05089916

Mar 2026

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study